Αρχική World News Majority of Patients With Cancer Are Willing To Be Vaccinated Against COVID-19

Majority of Patients With Cancer Are Willing To Be Vaccinated Against COVID-19

In order to better prepare the future vaccination campaign among patients treated or monitored for cancer, a group of investigators from France measured the willingness for the anti-SARS-CoV-2 vaccination in this population. They conducted a cross-sectional survey among ambulatory patients in four French cancer centres and found that a majority of patients who are under active cancer care or on surveillance are willing to be vaccinated against COVID-19. The findings are published on 29 January 2021 in the Annals of Oncology.

The authors wrote in the background that patients with cancer have a variable but confirmed higher risk of severe COVID-19. They advocate that patients with cancer should be a target population for vaccination, despite that they were excluded from the first trials.

The study team conducted the cross-sectional survey with an anonymous paper questionnaire from 11 November 2020 to 12 December 2020. Among the 1244 delivered questionnaires, 999 were returned (80.3%). The responding population included 56.1% of women, and the median age was 67 (range, 18-97).

Among the respondents, 47% were under active treatment (chemo- or immunotherapy and/or radiotherapy), 40% were under surveillance and 13% were under hormonal therapy.

The majority of surveyed patients received a flu vaccine in 2020 (54.3%) or in previous years (52.2%). A very small proportion of respondents reported that had COVID-19 (2.8%).

Among the respondents, 536 (53.7%) reported their intent to be vaccinated as soon as the vaccine was available, whereas 297 (29.7%) considered they were not ready yet but likely to change their mind. However, 166 patients reported to definitively refuse vaccination (16.6%).

Among patients in favour of vaccination, the main reasons were fear about their health (76.9%), the desire to protect their relatives (49.9%), the duty for collective responsibility (45.6%) and the wish to return to a normal life (38.7%).

Among patients who were not sure about vaccination, the arguments that could convince them to be vaccinated were to obtain more information on efficacy (59.4%), on safety (50.3%), on the type of vaccine administered (35.2%) and in only 7.4% collective responsibility or return to a normal life.

Among patients who did not support vaccination, the main reasons were the lack of confidence in the scientific results (88%), fear of side effects (30%) and believing that COVID-19 is benign in only few respondents (3.6%).

The predictors for vaccination acceptance in multivariate analysis were history of influenza vaccination, male sex and age older than 69 years.

Majority of the respondents considered that the oncologists are qualified to advise the patients in terms of vaccination.

The authors underlined that the studies with stratification according to the type of treatment and the type of vaccine are a priority for the international oncology community.


Barrière J, Gal J, Hoch B, et al. Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey. Annals of Oncology; Published online 29 January 2021. DOI: https://doi.org/10.1016/j.annonc.2021.01.066



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...

New Task Force Focuses on Quality of Life for AYAs with Cancer

August 4, 2021, by NCI Staff Adolescents and young adults are using mobile devices to document the impact of cancer and its treatment on their...

Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC

Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on...